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ABSTRAK
Penyakit refluks gastroesofageal atau gastroesophageal reflux disease (GERD) merupakan suatu gangguan 
dimana isi lambung mengalami refluks secara berulang ke dalam esofagus, yang menyebabkan terjadinya gejala 
dan/atau komplikasi yang mengganggu. Berbagai penelitian epidemiologi menunjukkan adanya perbedaan 
secara regional dari segi prevalensi dan manifestasi klinik. Data regional juga menunjukkan peningkatan angka 
kejadian komplikasi seperti Barret’s Esophagus dan adenokarsinoma. Menanggapi situasi tersebut, pada tahun 
2004, para ahli GERD di Asia Pasifik termasuk Indonesia telah mengeluarkan suatu konsensus bersama untuk 
tatalaksana kelainan ini, kemudian direvisi pada tahun 2008.
Kemajuan teknologi kedokteran, khususnya teknik endoskopi gastrointestinal dan perangkat diagnostik lainnya 
seperti pH-metri 24 jam dan manometri, telah meningkatkan kemampuan penatalaksanaan GERD. Di sisi lain, 
pengetahuan dan kemampuan para dokter, baik dokter umum maupun spesialis penyakit dalam di negara kita 
dalam penatalaksanaan GERD yang adekuat, dirasakan belum merata. Begitu pula penyediaan sarana penunjang 
diagnostik dan terapeutik yang tidak sama antara satu daerah dengan yang lainnya. Pengurus Besar Perkumpulan 
Gastroenterologi Indonesia (PB PGI) memandang perlu untuk merevisi Konsensus Nasional Penatalaksanaan 
GERD di Indonesia tahun 2004, yang diharapkan akan menjadi suatu pedoman penatalaksanaan GERD.
Kata kunci: Barret’s esophagus, diagnosis,  endoskopi, GERD, manometri, pH-metri.
ABSTRACT
Gastroesophageal reflux disease (GERD) is a disorder, which gastric content repeatedly reflux into the 
esophagus causing disturbing symptoms and/or complications. Various epidemiological studies show that there 
is regional difference on the aspect of prevalence and clinical manifestation. Regional data also demonstrates 
increased incidence of complications such as the Barret’s Esophagus and adenocarcinoma. In response to the 
situation, the Asia-Pacific GERD experts, including Indonesia, had published a consensus on the management 
of GERD in 2004, which was subsequently revised in 2008.
Advances in medical technology, especially on gastrointestinal endoscopy technique and other diagnostic 
instruments such as 24-hour pH-metry and manometry, have improved the capacity of management of GERD. 
On the other hand, we feel that adequate knowledge and skills of doctors, both for general physicians and 
specialists of internal medicine in our country are not well-distributed. Moreover, the availability of instruments 
for diagnostic and therapeutical supports differs from one region to the others. The Organizing Committee of 
Indonesian Society of Gastroenterology or Pengurus Besar Perkumpulan Gastroenterologi Indonesia (PB PGI) 
considers that it is important to revise the National Consensus on the Management of GERD in Indonesia 2004, 
which is expected to be the guideline of GERD management.
Key words: Barret’s esophagus, diagnosis, endoscopy, GERD, manometry, pH-metry.
The Indonesian Society of Gastroenterology                                                              Acta Med Indones-Indones J Intern Med
264
INTRODUCTION 
In recent years, attention of the experts 
on gastroesophageal reflux disease (GERD) is 
increasing, either on the aspect of endeavors 
evaluating the pathogenesis, establishing 
diagnosis or on the aspect of management. 
Various epidemiological studies show that 
there is regional difference on the aspect of 
prevalence and clinical manifestation. In 
addition, regional data also demonstrates 
increased incidence of complications such as 
the Barret’s Esophagus and adenocarcinoma. In 
response to the abovementioned situation, the 
Asia-Pacific GERD experts, including Indonesia, 
had published a consensus on the management of 
GERD in 2004, which was subsequently revised 
in 2008.
Gastroesophageal reflux disease (GERD) 
is defined as a disorder, which gastric content 
repeatedly reflux into the esophagus causing 
disturbing symptoms and/or complications. 
The statement was proposed by the Asia-Pacific 
Consensus on the Management of GERD in 
2008 that stressing the word of “disturbing”, as 
it characterized the disturbance on quality of life 
and as an extraction of general opinion, which 
says that if esophageal reflux should be stated as a 
disease, it must affect the patients’ quality of life.1
GERD may also be regarded as a disorder that 
causes the reflux of gastric fluid and its various 
contents into the esophagus, causing typical 
symptoms such as heartburn (a burning sensation 
in chest, which is sometime accompanied 
with painful and stinging sensation) and other 
symptoms such as regurgitation (sour and bitter 
taste in mouth), epigastric pain, dysphagia and 
odynophagia.2 There are two groups of GERD 
patients, i.e. patients with erosive esophagitis, 
who are characterized by damages on esophageal 
mucosa as shown by endoscopic examination 
(the Erosive Esophagitis/ERD) and another 
group is patients with disturbing reflux symptom, 
but the endoscopic examination shows no 
damage on esophageal mucosa (Non-Erosive 
Reflux Disease/NERD).1
Advances in medical technology, especially 
on gastrointestinal endoscopy technique and 
other diagnostic instruments such as 24-hour 
pH-metry and manometry, have improved the 
capacity of management of GERD. On the other 
hand, we feel that adequate knowledge and 
skills of doctors, both for general physicians and 
specialists of internal medicine in our country are 
not well-distributed. Moreover, the availability 
of instruments for diagnostic and therapeutical 
supports differs from one region to the others. 
The Organizing Committee of Indonesian 
Society of Gastroenterology or Pengurus Besar 
Perkumpulan Gastroenterologi Indonesia (PB 
PGI) considers that it is important to revise 
the National Consensus on the Management of 
GERD in Indonesia 2004, which is expected to 
be the guideline of GERD management. During 
the process of compiling the consensus, the 
committee refers to various similar consensus 
issued by various centers worldwide, which are 
generally based on the evidence-based medicine. 
EPIDEMIOLOGY
GERD prevalence and complications in 
Asian countries, including Indonesia, is generally 
lower than the western countries; however, recent 
data shows that the prevalence is increasing. It is 
caused by changes of lifestyle that may increase 
the risk of GERD, such as smoking and obesity.1 
Epidemiological data in USA demonstrates 
that one of five aduls has esophageal reflux 
symptom (heartburn) and/or acid regurgitation 
once in a week and more than 40% of them have 
the symptoms at least once in a month.3 The 
prevalence of esophagitis in western countries 
shows a mean value ranges between 10-20%; 
while in Asia, the prevalence ranges between 
3-5% with an exception in Japan and Taiwan with 
a range between 13-15% and 15%. A recent study 
on the prevalence in Japan reveals a mean value 
of 11.5% and GERD is defined as the sensation 
of burning in the chest of at least twice a week.4,5
Until now, Indonesia has no complete 
epidemiological data on this condition. The 
available data is a report from a study conducted 
by Lelosutan SAR et al in Faculty of Medicine, 
University of Indonesia, Cipto Mangunkusumo 
Hospital, Jakarta (FKUI/RSCM-Jakarta), which 
demonstrates that of 127 study subjects who 
underwent upper gastrointestinal endoscopy, 
22.8% (30 subjects of them) had esophagitis.6 
Another study conducted by Syam AF et al.7, 
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which is also from RSCM/FKUI-Jakarta, 
shows that of 1718 patients who underwent 
upper gastrointestinal endoscopy on indication 
of dyspepsia for 5 years (1997-2002), there is 
an increased prevalence of esophagitis, from 
5.7% in 1997 to 25.18% in 2002 (mean value of 
13.13% per year).7
Some risk factors for GERD have been 
evaluated in Asia-Pacific population, including 
elderly age, male, race, family history, high 
level of economic status, incrased body mass 
index and smoking. The strongest evidence is 
provided for association of certain risk factors 
wih the development of GERD in Asia-Pacific 
population, i.e. the increased body mass index 
and more than 25 clinical studies have supported 
the correlation.8
DIAGNOSIS
Careful history taking is the main method 
to establish GERD diagnosis. Specific symptom 
of GERD is heartburn and/or regurgitation 
that occur after meal. However, it should be 
emphasized that most of diagnostic studies 
of heartburn and regurgitation symptoms are 
performed in Caucasian population. In Asia, 
the symptoms of heartburn and regurgitation 
are not the typical features for GERD. However, 
the experts have agreed that both symptoms are 
characteristics for GERD.1
In a tertiary referral hospital, before performing 
endoscopic examination to establish the diagnosis 
of GERD, other further investigation (laboratory, 
ECG, USG, chest X-ray and other investigation 
in accordance with the indication) should be also 
carried out to exclude diseases with symptoms 
similar to the GERD. The Asia-Pacific experts have 
stated by acclamation that the regional strategy of 
diagnostic GERD must consider the possibility 
of GERD exists with other comorbidities such 
as gastric cancer and peptic ulcer. However, 
regarding the H. pylori test to exclude infection 
in patients with GERD symptoms in regions with 
high prevalence of gastric cancer and peptic ulcer, 
there is a controversial opinion of the experts. 
Nevertheless, the test is still recommended by 
considering risk factors including comorbidities, 
age, histological profile of the stomach, family 
history and patient’s preference.1
GERD-Q
GERD Questionnaire (GERD-Q) (Table 
1) an instrument of questionnaire developed to 
assist establishing the diagnosis of GERD and 
measuring response to therapy. The questionnaire 
is developed based on clinical data and 
information obtained from high-quality clinical 
Table 1. GERD-Q
Try to recall what you have experienced in the last 7 days.√
Put a check mark (√) only at one single space for each question and count your total GERD-Q score by doing summation 
of the point(s) for each question. 
No. Question
Frequency of score (point) for symptoms
0 day 1 day 2-3 days 4-7 days
1. How often do you experience the sensation of burning behind your 
breastbone / sternum (heartburn)?
0 1 2 3
2. How often do you experience the gastric content backing up into your 
throat / mouth (regurgitation)?
0 1 2 3
3. How often do you feel epigastric pain? 3 2 1 0
4. How often do you feel nauseated? 3 2 1 0
5.
How often do you have difficulty to have night sleep due to the 
burning sensation in the chest (heartburn) and/or the backing up of 
abdominal content?
0 1 2 3
6.
How often do you take additional medication for treating the 
burning sensation in the chest (heartburn) and/or the backing up 
of abdominal content (regurgitation), other than prescribed by your 
doctor? (such as the over the counter drugs for treatment of stomach 
complaints) 
0 1 2 3
Result
If your GERDQ points <7, you probably do 
not have GERD. If your GERDQ points is 
8-18, you probably have GERD
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studies as well as from qualitative interviews 
with patients in order to evaluate the simplicity of 
filling up the questionnaire. GERD questionnaire 
is a combination of validated questionnaires used 
in the DIAMOND study. Improved accuracy 
of diagnosis by combining several validated 
questionnaire will increase the sensitivity and 
specificity of diagnosis.9,10
An analysis on more than 300 patients at a 
primary health care service demonstrates that 
GERD-Q may provide sensitivity and specificity 
of 65% and 71%, which is similar to results 
obtained by gastroenterologists. Moreover, 
GERD-Q also shows the capacity to evaluate 
relative impacts of GERD on patients’ life and 
to provide assistance in selecting therapy.9
Table 1 is the GERD-Q that can be filled 
up by the patients themselves. For each 
question, respondent should fill up according 
to the frequency of symptoms that they have 
experienced in a week. Score 8 or more is the 
recommended cut-off point to detect individuals 
with high tendency to have GERD.10 GERD-Q 
has been validated in Indonesia.
Upper Gastrointestinal (UGI) Endoscopy
Upper gastrointestinal endocopy (UGIE) is 
considered the gold standard for establishing 
the diagnosis GERD with erosive esophagitis. 
Using the UGIE, we can find the mucosal break 
of esophagus. Endoscopy in GERD patients is 
mainly used for individuals with alarm symptoms 
(progressive dysphagia, odynophagia, weight 
loss with unexplained etiology, new onset of 
anemia, hematemesis and/or melena, family 
history of gastric and/or esophageal malilgnancy, 
chronic use of NSAID medication, individuals 
with age over 40 years in a region with high 
prevalence of gastric cancer) and for those who 
do not response to empirical treatment using PPI 
twice daily.1,11,12
While until now, there is no gold standard 
for diagnosis of NERD. The following criteria 
is used as the guideline for establishing the 
diagnosis of NERD:1
• No mucosal break found in the upper 
gastrointestinal endoscopy,
• Positive results on esophageal pH test, 
• Twice-daily empirical therapy with PPI gives 
positive response.
Endoscopy for GERD is not always 
performed on the first visit since the diagnosis 
of GERD can be made based on symptoms 
and/or empirical therapy. The roles of upper 
gastrointestinal endoscopy in establishing the 
diagnosis of GERD are:
• Confirming the presence and absence of 
esophageal damages including erosion, 
ulceration, stricture, Barret’s esophagus or 
malignancy, in addition to excluding other 
upper gastrointestinal abnormalilties.
• Evaluating the severity of mucosal break 
using modified Los Angeles classification 
or Savarry-Miller classification.
• Biopsy specimens are taken when there 
is a suspicion of Barret’s esophagus or 
malignancy.
Histopathological Examination
Histopathological examination as the 
diagnostic tool of GERD is essential to 
determine the presence of metaplasia, dysplasia 
or malignancy. No supporting evidence has 
been provided about whether biopsy specimen 
is needed in NERD cases. In the future, further 
studies on the role of high-resolution (magnifying 
scope) endocopy in NERD cases are necessary.
24-hour pH-metry Test
The roles of conventional 24-hour pH-metry 
test or 48-hour capsule (if available) in the 
diagnosis of NERD are:13,14
• Evaluating GERD patients who do not 
respose to PPI therapy.
• Evaluating whether the patients are those 
with extra-esophageal symptoms before the 
PPI therapy or after failed PPI therapy.
• Confirming the diagnosis of GERD prior to 
anti-reflux surgery or evaluating symptoms 
of NERD repeatedly following the surgery.
PPI Test
PPI test can be performed to establish the 
diagnosis in patients with typical symptoms and 
without alarm signs or risk for Barret’s esophagus. 
The test is carried out by administering double-
dose PPI for 1-2 weeks without the preceding 
endoscopy examination. If the symptoms subside 
with PPI administration and recur when the PPI 
treatment is stopped, then the diagnosis of GERD 
can be made. The test is considered as positive 
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result, if there is clinical improvement of more 
than 50% in 1 week.1,11,15
A meta-analysis study demonstrates that 
PPI test has a sensitivity of 80% and specificity 
of 74% for establishing diagnosis of GERD 
patients with non-cardiac chest pain. It indicates 
that PPI test can be considered as a useful 
strategy and probably has economic value in 
management of patients with non-cardiac chest 
pain without alarm signs of suspected esophageal 
abnormalities.16
Other Diagnostic Tests
Alternative tests that can be performed other 
than endoscopy and pH-metry are:
• Barium esophagography. Although this test 
is not sensitive for GERD diagnosis, but 
in certain condition the test provides more 
advantages than endoscopy, i.e. in the case 
of esophageal stenosis and hiatal hernia.
• Esophageal manometry. The test has 
advantages, particulary for evaluating 
treatment of NERD patients and for the 
purpose of research.
• Impedance test. This new method can detect 
the presence of gastroesophageal reflux 
through altered resistance against electrical 
current between two electrodes when fluid 
and/or gas move between them. The test is 
mainly useful for evaluating NERD patient 
who does not response to PPI therapy; in 
which the documentation of non-acid reflux 
will change the management approach.14
• Bilitec test. The test can detect the presence 
of gastroesophageal reflux by using the 
characteristics of optical bilirubin. The test is 
essential, particularly for evaluating patients 
with persistent symptoms of reflux despite 
the normal result of pH-metry when they 
have acid exposure on distal esophagus.14
• Bernstein test. The test measures the 
sensitivity of esophageal mucosa by installing 
trans-nasal catheter and perfusion on distal 
esophagus with HCl 0.1 N in less than an 
hour. The test is a complementary to 24-
hour esophageal monitoring pH in patients 
who had atypical symptoms and for research 
purpose.
Surveilans Barett’s Esophagus
The role of endoscopy surveillance in patients 
with Barrett’s esophagus is still controversial 
even in the countries with high prevalence. In 
Asia, the prevalence of Barret’s esophagus is still 
low, which is reported about 0.08%. Meanwhile 
in the United States, it is reported that the 
incidence of esophageal cancer in patients with 
Barret’s esophagus is about 0.4%; while other 
studies reported that it ranges between 1-2%.1,17
Up until now, the screening test for Barret’s 
esophagus is still controversial due to less impact 
of the screening test on mortality of esophageal 
adenocarcinoma. Surveillance endoscopy is 
suggested for individuals with high risks and it 
should be performed according to the grade of 
dysplasia found. For futher discussion, please 
refer to the associated references.17
MANAGEMENT
Management means the action performed 
by doctors who treat GERD cases, including 
non-pharmacological therapy, pharmacological 
treatment, endoscopy and surgery. Basically, 
there are 5 targets that should be achieved and 
must always be a concern when we plan, change 
and stop the therapy for GERD patients. The five 
targets are eradicating symptoms/complaints, 
recovering esophageal lesion, preventing 
recurrent illness, improving quality of life and 
preventing the development of complications. 
This guideline of management is expected to be 
applied in the primary, secondary and tertiary 
health care services.18-20
The clinical approach on the management of 
GERD includes treatment of GERD (NERD and 
ERD), refractory GERD and non-acid GERD. 
In the first line, the diagnosis of GERD is made 
more based on clinical symptoms and symptom-
based GERD questionnaire. The management is 
provided based on clinical diagnosis (Figure 1).
Non-pharmacological Treatment 
The main concern is targeted on modifying 
overweight and elevating head around 15-20 
cm during sleep as well as other additional 
factors such as smoking cessation, stop drinking, 
reducing food intake and medications that 
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stimulate gastric acid and causing reflux, less 
satiating feeding and last evening meal at least 
3 hours before bedtime.21
Pharmacological Treatment 
There are drugs that have been known to 
have capacity to overcome GERD symptoms, 
which include antacids, prokinetics, H2-receptor 
antagonists, Proton Pump Inhibitor (PPI) and 
Baclofen.22 The effectiveness of each drug class 
is shown in Table 2.
Of all the abovementioned drugs, PPI is the 
most effective drug in eradicating symptoms and 
recovering esophagitis lesion in GERD.9 PPI 
has been proven providing more rapid recovery 
on esophagitis lesion as well as eradicating 
GERD symptoms compared to the H2 receptor 
antagonists and prokinetics. If PPI is not 
available, H2RA can be administered.24-26
In individuals with heartburn symptom or 
episodic regurgitation, the use of H2RA (H2-
Receptor Antagonist) and/or antacids can be 
helpful to provide rapid symptom eradication. 
Moreover, in Asia, the use of prokinetics 
(dopamine antagonists and serotonin receptor 
antagonist) may be beneficial as adjunctive 
therapy (Figure 2).1
GERD treatment can be started with PPI 
after the diagnosis of GERD has been established 
(see diagnosis section). The initial dose of PPI 
is single dose each morning before meal for 
2 – 4 weeks. If there GERD symptom is still 
found (PPI failure), PPI should be administered 
continuously in double dose until the symptoms 
has been eradicated. In general, double-dose 
therapy can be given up to 4-8 weeks (Table 3). 
If there is no clinical improvement, endoscopy 
must be done to confirm the presence of any 
abnormality in upper gastrointestinal mucosa. 
Further treatment can be given according to the 
severity of mucosal damage.29
For mild esophagitis, the treatment may be 
followed with ‘therapy on demand’ strategy. 
While for severe esophagitis, it can be followed 
with continuous maintenance therapy, which may 
be given up to 6 months.1,11,12
Grade A and B are included in clinical 
category of mild esophagitis. Grade C and D 
are the clinical category for severe esophagitis.
Suspect GERD
GERD-Q
(-) not GERD (+) GERD
Alarm symptom
Negative Positive
PPI test Refer
Negative Positive
GERD
8-week GERD
therapy
GERD negative GERD positive
Figure 1. Algorithm of treatment based on diagnostic process 
in primary health care services
Table 2. Effectiveness of drug treatment for GERD23
Drug Class
Improving 
symptoms
Recovering 
esophageal lesion
Preventing 
complication
Preventing 
recurrent illness
Antacids +1 0 0 0
Prokinetics +2 +1 0 +1
H2-receptor antagonists +2 +2 +1 +1
H2-receptor antagonists and 
prokinetics +3 +3 +1 +1
High-dose H2-receptor 
antagonists +3 +3 +2 +2
PPI +4 +4 +3 +4
Surgery +4 +4 +3 +4
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For NERD, initial treatment can be provided 
by giving single dose PPI for 4-8 weeks. After 
the clinical symptoms diminish, therapy can be 
followed with PPI on demand. The ‘on demand’ 
treatment is suggested in order to maximize 
gastric acid suppression, which is administered 
in 30-60 minutes before breakfast.1,11
GERD, which is refractory to PPI therapy 
(no response to PPI therapy of twice daily for 8 
weeks) must be confirmed by reevaluating the 
GERD diagnosis using endoscopy to confirm 
the presence of any esophagitis. If no esophagitis 
is found, the investigation is followed with pH-
metry test.
Based on the results of pH-metry, we 
can determine the dominant factor for reflux 
of gastric content, either by hyperacidity or 
pathological anatomy factors such as (SEB 
disorder, hiatal hernia, etc). If the pH-metry 
demonstrates the domination of pathological 
anatomy factors and the clinical symptoms are 
still there, the diagnostic test using esophageal 
impedance and pH can be considered (Figure 
3) to confirm the next therapeutical measure 
(tertiary treatment measure).1,11
Now, the treatment for non-acid reflux 
(NAR) is still developing. Studies on Baclofen (a 
GABA-B agonist) has provided promising results; 
however, further data is needed to recommend 
the drug routinely.30,31 The recommended 
treatment includes avoiding large and late meal, 
maintain head up position until 3 hours after 
the meal, reduced body weight and head-up tilt 
sleeping. However, no study has confirmed that 
such treatments are clinically significant.
Uninvestigated typical reflux symptom
Alarm symptoms
present
History
GERQ
PPI Test
No alarm
symptoms
Empirical therapy with PPI for 4 weeks
and evaluation in 2-4 weeks
H2RA if no PPI is available
- Endoscopy
- Radiology
- pH-metry
Persistent symptoms improved symptoms
Impedance
Esophageal manometry
Gastric scintigraphy
Try to stop PPI
Relapse
Frequent relapse
or alarm symptoms
Therapy
on demand
Start readministering
PPI
Figure 2. Algorithm of treatment based on diagnostic process in secondary and tertiary 
health care services.1
Table 3. PPI dose for GERD treatment27,28
PPI types Single Dose Double dose
Omeprazole 20 mg 20 mg twice daily
Pantoprazole 40 mg 40 mg twice daily
Lansoprazole 30 mg 30 mg twice daily 
Esomeprazole 40 mg 40 mg twice daily
Rabeprazole 20 mg 20 mg twice daily
Table 4. GERD classification based on endoscopic 
results29
NERD
ERD
Grade A Grade B Grade C Grade D
Mucosal 
break (-)
No 
mucosal 
damage
Diameter 
<5 mm, 
single
Diameter 
<5 mm, 
several 
lesions, 
colonized
Diameter 
>5 mm, 
single, 
several 
lesions
Lesion 
encircling 
the 
lumen
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Other lifestyle interventions such as smoking 
cessation and stop drinking alcohol as well 
as changing the pattern of food intake can 
significantly reduce the symptoms of GERD.21 
Modified life style is used as the first line therapy, 
such as reducing body weight, reducing smoking, 
stomach emptying of more than 3 hours before 
bedtime.1 A recent systematic study shows that of 
all lifestyle intervention, only weight reduction 
and head-up tilt sleeping that affect the GERD 
symptoms significantly.
Now, the consensus on the management 
of GERD, both the Asia-Pacific and American 
Consensus, do not suggest excessive lifestyle 
changes in the management of such condition.1,19 
It is suggested since altered lifestyle does not 
significantly reduce GERD symptoms and causes 
excessive stress to the patients. However, based 
on a meta-analysis conducted on those lifestyle 
factors, the Asia-Pacific consensus suggest to 
do modifications on overweight and head-up 
tilt sleeping.1
Endoscopic Treatment 
GERD complications such as Barret’s 
esophagus, esophageal stricture, stenosis or 
bleeding can be treated with endoscopy using 
Argon plasma coagulation, ligasi, Endoscopic 
Mucosal Resection, bougination, hemostasis or 
dilatation.
Endoscopic treatment for GERD is still 
developing and until now it is still in the context 
of research. Endoscopic treatments that have 
been developed are:
• Radiofrequency energy delivery
• Endoscopic suturing
However, there is still no report available 
on endoscopic treatment for GERD until now 
in Indonesia.
Surgical Treatment 
Surgical treatment includes antireflux 
surgery (Nissen fundoplication, corrective 
surgery for hiatal hernia, etc) and surgery to 
fix complications. Antireflux surgery (Nissen 
fundoplication) can be suggested for patients 
who are intolerant to maintenance therapy or 
those who with persistent disturbing symptoms 
(refractory GERD). Available studies show 
that if it is performed well, the effectiveness 
of the antireflux surgery is equal with medical 
treatment; however, it brings side effects such 
as dysphagia, bloating, difficulty in burping and 
intestinal disorder following the surgery.1,12,32
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